Last reviewed · How we verify

Zurex Pharma, Inc. — Portfolio Competitive Intelligence Brief

Zurex Pharma, Inc. pipeline: 1 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Chloraprep Chloraprep marketed Other
ZuraPrep Clear Solution ZuraPrep Clear Solution phase 3 Transdermal Drug Delivery
ZP Vehicle ZP Vehicle phase 3
ZuraPrep with 70% IPA ZuraPrep with 70% IPA phase 3 Skin preparation solution Surgical site preparation
ZuraPrep without 70% IPA ZuraPrep without 70% IPA phase 3 Topical antiseptic Surgical site infection prevention
ChloraPrep CHG/IPA Teal Tint ChloraPrep CHG/IPA Teal Tint phase 3 Topical antiseptic combination Infection Prevention / Surgical Antisepsis

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Professional Disposables International, Inc. · 2 shared drug classes
  2. Case Western Reserve University · 1 shared drug class
  3. Central DuPage Hospital · 1 shared drug class
  4. Hospital Regional de Alta Especialidad del Bajio · 1 shared drug class
  5. Instituto de Investigacion Sanitaria La Fe · 1 shared drug class
  6. Johnson & Johnson Consumer Inc. (J&JCI) · 1 shared drug class
  7. Poitiers University Hospital · 1 shared drug class
  8. Solventum US LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zurex Pharma, Inc.:

Cite this brief

Drug Landscape (2026). Zurex Pharma, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zurex-pharma-inc. Accessed 2026-06-10.

Related